Q1 2023 Alnylam Pharmaceuticals Inc Earnings Call
The reminder, today's conference call is being recorded.
I would now like to turn the conference over to the company. Please go ahead.
Good morning, I'm, Christine the number I'm senior Vice President of Investor Relations and corporate communications that on an island with me today on the phone or a on Green Street, Chief Executive Officer until the Dangler too commercialized, Sir Okay based on precedent and Jeff Fulton Chief Financial Officer.
One of the room and available for Q&A as political guard, our Chief Medical Officer.
To participate in via conference call for five can be access by going to the events section of the investors page of our website investor's dot on the island Dot Com slash about.
Today's call as outlined by two of on will offer some introductory remarks provide general contact.
Oh, well, we'll provide an update on our global commercial progress.
Okay, We'll review pipeline updates and clinical progress and Jeff will review, our financial some guidance followed by a summary of upcoming a milestone before we open the call for your question.
I'd like to remind you that this call will contain remarks concerning it on my own future expectations plans on prospect, which constitute forward looking statements for the purposes of the Safe Harbor provision private Securities Litigation Reform Act 1995.
Actual results may differ materially from that authenticated by these forward looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the S. A T.
<unk> any forward looking statements represent our fees only as the date of this reporting it should not be relied upon as representing our views as of any subsequent date specifics.
Specifically disclaim any obligation to update such statements with that I will turn the Colorado Ivan Ivan.
Thanks, Christine and thank you everyone for joining the cool today.
2023 is off to a great start with future loans, continuing with strong growth with kiwanja delivering 48% growth.
Total product sales compared to the first quarter of 2022.
Also made great strides without pipeline, including the recent exciting announcements of positive interim results from the phase one study if L. M. A P. P. R investigational aren't they like therapeutic and development for the treatment of outside with the cities and cerebral amyloid angiopathy.
We believe they establish human proof of concept therapeutics.
<unk> six in the CNS and potentially unlock many additional opportunities, where we may be able to address significant unmet medical needs.
We also have a number of exciting upcoming milestones the highlight the depth and breadth about pipeline, which includes the presentation of 18 months results from the Apollo be phase III study <unk>. It's D. S. C. H F. Later this month and top line results from the cardio one phase two study <unk> and patience.
With hypertension expected in mid 2023.
This is execution is in line with our focus on the following key drivers from items growth over the next several years.
Trust is the potential mid term expansion of our T. T. R franchise opportunity, where we aim to become a global Lisa and delivering impactful and highly differentiated medicines to patients.
Second is our expansion beyond rare diseases to also address more common disease areas.
And a third group driver for the company comes from a sustainable innovation Angela comprised of new platform enhances opportunities with extra had perfect delivery.
And our ability to find new genetically validated sockets, which can drive further pipeline expansion to 2025 and beyond.
We believe all of this puts us on track with our Madam Pizza fifth by 25 calls make you an item of top tier patek, developing and commercializing transformative medicines for rare diseases I'm beyond the patients around the world driven by a high yielding pipeline. The first annual best in class products.
Candidates from our organic product answered all while delivering exceptional financial results with that let me now turn the call over to toga for review about commercial performance TADA. Thanks.
Thanks to God and good morning, everyone.
Two one was a strong quarter for our commercial portfolio driven by our teacher, our franchise and the strength of our ongoing launch off I'm withdrawal as we delivered 48% total product sales growth.
52 per cent on a constant exchange rate basis, compared with the first quarter of 2022.
Let me now turn to a summary of our first quarter GTR performance.
R. T. G. R franchise achieved $204 million in global net product revenues from Petra <unk>, representing a 7% increase compared with the fourth quarter and a solid 49% growth compared with the first quarter of 2022.
With the U S market year over your ear growth standing out at a robot, 75% driven by the ongoing launch of <unk>.
At the end of the first quarter over 3160 patients were on commercial on petrol or what's our treatments worldwide.
From over 2975 patients at the end of the fourth quarter, representing 6% quarterly patient growth.
In the U S. Combined sales of on paths right would try increased 5% versus the fourth quarter and or primarily impacted by the following.
It's seven per cent increase in demand, which was driven by the strength of ongoing download to a patient uptake more than offsetting the decrease in patients on on Petro that switch to <unk>.
Tori dynamics decreased reported growth by approximately 3%.
Inventory in the channel continues to decrease with ongoing patients switching to <unk>.
Overall in the U S. We continue to be very pleased with the impact we're seeing from <unk> in expanding do a portrait itchy for our TCR franchise is reflected by the robust 75%.
Over a year quarterly growth that'd be achieved in Q1.
Representing the third consecutive quarter of achieving T. T R growth in excess of 70% on a year over year basis in the U S. Following which was launched in the third quarter of 2022.
Additionally, key operating metrics continues to transfer favorably including growth in new patient start forms.
Switched rates Rahman Petro patient compliance rates and the expression of our prescriber base.
International markets.
Total T T R. Two one product sales increased 9% versus the fourth quarter.
By strong demand in Japan.
Knowing the fourth quarter launch of our truck offset by inventory Destocking in Japan.
And what's a demand growth in Japan is particularly encouraging with a new patient growth being driven by a mix of switches from tafamidis as well as patients naive to therapy.
Additionally, any reportedly on petrol continue to deliver steady growth in markets, where which was not yet launched.
Issuing these markets for the upcoming Amato launch.
I'll patch will also benefit from tightening the borders in our distributor markets.
Our global results continue to be challenged by foreign exchange headwinds totaled.
Hotel T T R year over year reported the growth of 49% held back five percentage points due to changes in that fixed rates.
Now moving to our ultra rare products and the performance of give <unk>, which delivered $72 million in combined product sales during the first quarter, representing a 2% increase compared with the fourth quarter and a more robust 45 per cent growth compared with the first quarter of.
2022.
Forgive already Oxford, respectively.
Laurie global growth of 2% in Q1, compared with the fourth quarter was impacted by the following.
Associated with the seasonal impact from the annual Preauthorization required by payers during the first quarter.
We expect will recover in subsequent quarters.
Growth in our international markets increased 11% is that an increase in European markets and also benefited from the tightening the borders at our distributor markets.
For a global global growth of one per cent in Q1 compared with the fourth quarter was impacted by the following U.
U S reported growth increased 3%.
Driven by an increase in patient demand.
Growth in international markets was flat with a demand increase in European markets offset by the timing of orders that our distributor markets.
Additionally, changes in year over year Court exchange rate negatively impacted Q1, <unk> silver reported growth by three and four percentage points respectively.
In conclusion, we.
We are pleased with the growth in revenues, particularly with the ongoing sides of strong performance.
<unk>, what's your launch, which we believe represents an important therapy option for a J T. G. R ambiguous as patients with Polyneuropathy and accelerated growth opportunity for our T. T R franchise.
With that I will now turn it over to Akshay to review, our recent R&D and pipeline progress Akshay, Thanks tall Guy and good morning, everyone.
I'd like to start today.
With a recap of recent news that monks are very important milestone for an item and the broader field of already on a therapeutic which is our progress with Alan ATP, an investigation alrighty therapeutic in development for the treatment of Alzheimer's disease, and cerebral amyloid angiography.
That was announced last week, we reported the first ever clinical results with an army of my therapeutic directed to the CNS.
Given the importance of the pulse of data and the intense interest in this study from all parties concerned not least patients and physicians.
Think it's worthwhile to further discuss being driven finding strong Ral N. A P. P program.
Ellen IPP targets amyloid precursor protein or a P P, which were investigating as a potential treatment for Alzheimer's disease, and cerebral amyloid angiopathy or C. I a.
Human genetics has shown that certain mutations will duplications in the IPP Jean can cause early onset Alzheimer's disease, or amyloid plaques, forming brain tissue and are associated with Nero degeneration.
Other mutations in the same gene conclude CIA or a beta Franklin as distinct from those that aggregate to form Alzheimer's plot deposit within the blood vessels in the brain and result bleeds.
C. I a is in fact, the second leading cause of interest to remove haemorrhage. So there's one parent protein IPP can be harmful into distinct pathophysiological processes.
And animal studies, we have shown that having a P. P with an S. On a show great promise with broad CNS Biodistribution after singled injure fetal injection echo on the left here.
<unk> knocked down and we will major CNS, all types, which was the neurons <unk> micro beer and exercise.
On the right, we can see that a single 60 milligram interest equal dose and nonhuman primate is results insignificant and sustain target knockdown durable durability. After six months at which time the experiment was terminated but Avp's depression was still ongoing.
These phone closet findings, which were reliable reproducible and appeared safe increased our assignment around the therapeutic hypothesis, specifically that by lowering IPP protein production in the San espionage mechanism, we could reduce the downstream fragments that aggravate and deposit and tissues.
Therefore, hopefully both of the disease course.
The support advancement to clinical testing, we conducted short term I'm, enabling GOP toxicology studies, and the rat and nonhuman primate, but too low medium and high doses were given a month apart.
R E, where we greatly exaggerated exaggerates dose and regiment relative to that expect could be the clinic.
This study has demonstrated to the supporters safety profile and no significant San Francisco pathology, and thereby enable DLNA APB phase one study.
The phase one trial is designed as a two part study Ah single, sending those are a followed by multiple dose puppy.
But he was enabled by the GOP toxicology studies I've just mentioned.
Phase one is being conducted in patients with early onset Alzheimer's disease.
The primary on point of this study's safety and Tolerability a valid IPP secondary objectives are focused on characterizing the pharmacology of add an a P. P.
The study also includes a variety of exploratory biomarkers, which will allow us to assess by the ellena AVP showing any impact on other biomarkers of disease progression.
The interim data shared from the initial single is sending those codes and we continue enrolling in pot a as we explore further doses.
[noise] excuse me.
At the time of this interim look 20 patients with early onset Alzheimer's disease I've been enrolled in three single dose cohorts and part of the ongoing phase one study.
To date, Ellen APB has been well tolerated no study dropouts and all adverse events be mild or moderate in severity.
Available CSF data from white blood cells and protein appear similar placebo.
Filament light chain or NFL, which is a mock of neuro damage and which may be elevated and drug induced neurotoxicity was also <unk>.
Racial reassuringly early data for NFL, which are currently available from two three cohort study today.
Looked comfortable.
Yeah.
Now, let's look at the family dynamic results off the single interesting doses.
To date, we've studied three types levels, 25, 50, and 75 milligrams.
All available <unk>.
All available data.
All available data to the three months time point Sharon.
Citing Lee we observed that unlike placebo.
And an APB treatment resulted in rapid dose dependent and sustain reductions of both S. S. A P P alpha and soluble APB beta.
Both my mom because of target engagement in the CSS.
We so rapid knocked down as early as 815 and.
The maximum knockdown of up to 80 490 per cent, respectively prey P. P Alpha beta.
The highest those tested 75 milligrams immediate lockdown was greater than 70%, but both biomarkers and sustained for at least three months.
Initially per protocol, we intended to those escalate from 75 to 225 milligrams. However, given that the knockdown observed at 75 milligrams substantially exceeded our initial target of 50 per cent biomarker knock down we chose to Deescalate the 50 milligrams.
As you can see at 50 milligrams, while we have more limited data set it appears equally promising and similar to the 75 milligram dose with substantial note, both APB Alpha and beta.
Now, notably the durability, we seen humans reflects what we saw in on your primary studies was single doses gave similar profound durable knockdown extending to six months or beyond.
Accordingly, we anticipate that the responses, we see here in Pompeii will continue indeed.
Indeed for the date available beyond three months and deceiving study, we see continued targets oppression.
This durability of effect is important for an APB as well as our overalls and assesses access.
Suggests the potential for infrequent dosing.
We look forward to seeing with longer follow up indeed, how long this knock on effect is the same.
I believe these days suggests that the drug will be able to be dose 40th most and price of animal based in the translation of our platform in humans believe them substantial to even dose every six months or less frequently.
Enrollment in the singular sending those portion of the phase one study is ongoing in Canada, Netherlands, U K and the United States.
Additionally, enrollment in Pantel, you will allow us to continue to explore single dose P. M. P D and characterize the durability and effects longer and long term safety.
Results from parts of it will also inform the doses and regiments forwards into pop be multiple dose portion of the study which will include patients from pate.
And paneled upon a of the phase one study we conducted chronic GOP toxicology studies in animals to support the multi those puppy face one.
He's chronic GOP talk studies were conducted without knowledge of impressive knocked down and durability received today at low doses violent ATT.
We've seen this phase one study so.
The standard practice, we exaggerate doses and dosing frequency relative to any toes and regiment that would ultimately ultimately be used in clinical testing.
Specifically, we administered low medium and high interest equal doses monthly for six months and the rat and every other month nine months.
<unk>.
The data from the chronic studies to be sure to regulate foreigners.
The board we have already received regulatory approval to begin policy in Canada, where in fact, the majority of the putting patients enrolled.
An improvement as pending in the UK metal.
And the U S. The Fda's currently place possible clinical hold on the market is copy of the phase one study.
Due to findings.
Toxicology studies.
Of course, given the high exposure that we achieved with frequent administration with high doses someone unexpected that we would observe findings Denise calling toxicology studies.
However, it's important to contextualize exposures by relatives csf's volumes between toxicology species in humans.
For example, relative to a potential clinical dosing regimen of 75 milligrams, given every six months or more than 10 fold greater annualized exposure at all doses tested in the wrath of nonhuman primate.
And at the top doses evaluate this chronic talk studies, there's a 75 and 50 fold greater annualized exposure in rack and they'll give you a prime minster, respectively relative to the same potential human dose.
And if we scale based on organ way than these annualized exposures would be even greater than the chronic talk studies.
I want to nevertheless, acknowledge that the F. D. A will be the ultimate arbiter of the data and we look forward to getting further guidance from them. Accordingly, we plan to engage with them to discuss all preclinical information as well as these new interim phase one clinical data, which provides important context to support potential initiation of puppy in the U S.
The closest part of the discussion I'm absolutely thrilled about these incredible human data that provide the first ever evidence that we may be able to use an AI sinus disease, causing transcript and the CNS Nana.
Animal studies, we've already demonstrated the reproducible modular nature of vaccine is platform with the knocked down against the diverse range of targets and hope that we can address disease, causing genes not just for alzheimers.
L as in Huntington, but also have many other disorders.
We look forward to presenting these interim dates from pot a off the face on the Atlantic.
At an upcoming medical Congress.
With that let me turn at our efforts and a teacher amyloidosis, where we are advancing three clinical studies product candidates mainly <unk>.
And LNP Trs here before.
As you know on Patrick's currently approved with multiple markets around the world to treat hereditary tombola doses with pulling uropathy and we're committed to expanding the product label for the treatments cut them off the tree.
<unk> and wild type 80 traveler doses patients.
When I was in February with delighted that our supplemental new drug application <unk> cut them up you have a teacher amyloidosis has been accepted by the FDA with the standard review and it produced the date of October 8th.
And that filed acceptance latter the FDA stated that they are not identified any review issues.
Also noted that they are planning to hold an advisory committee meeting to discuss the application <unk>.
Currently we have no further details from yesterday regarding the timing of theatrical August specific topics I wish to discuss when.
When we learn more we will communicate that information in due course if.
If the Sandy is approved this will allow us to extend the potential benefits of police run many patients with one time <unk> doses with cardiomyopathy.
This finding is based on the pivotal Apollo B study, which demonstrated improved functional status and quality of life in patients with a teacher amyloidosis with cardiomyopathy, given police around for 12 months.
Receiver.
The clinical profile <unk> is supported by encouraging safety profile and <unk> data that favored produced on treatment lawsuit placebo embarrassed by amongst these progression at 12.
We've announced this morning that 18 months dates from the Apollo B studies, you've been submitted to the F. D. A is part of the S. N da reviewed and we will be presenting these results at the <unk> at the end of May.
Similar to <unk> committed to expanding the labor for Abu trips to include the treatment of cardiomyopathy in both of the tree and wall type a teacher amyloidosis.
This is being done with the Helios be phase three study of investigation will be <unk>.
B, which is fully enrolled as men point of all cause mortality and C. V events assessed after at least 30 and up to 36 months and we remain on track to share topline results in early 2024.
Wrapping up with <unk> as an investigation of RNA my therapeutic based on that I carry a platform and offers the potential for more durable and potent detail silencing with the possibility for annual Dyson potentially transformative profile.
<unk> has entered the clinic and they become and begun <unk> study and we expect topline results in late 2023.
In addition to our license plates clinical programs. We believe we've also been making great progress without early and mid space programs. Notable highlight includes all beachfront. Our investigation wondering like therapeutic five attention, which we believe could transform the treatment of the disease and offer a highly differentiated profile from all existing antihypertensive, including or <unk>.
<unk> <unk>.
We look forward to the upcoming milestones from the phase two program and remain on track to deliver top line results from County, one in mid 2023.
Klein results, we call you too at or around here and 23.
These are just a few of the highlights from a broad and innovative pipeline driven by underlying organic product engine and that we were we expect to deliver sustainable innovation, representing a keto Craig's driver file an island in the years to come.
To wrap up these highlights we're excited to have initiated posing in the phase one study of Ireland K K for the potential treatments type two diabetes, plus regeneron as announced initiation of phase two study and an H H S. D impatience with Nash now with that let me now turn it over to Jeff financials about putting miles, but it's Jeff.
Thanks talk show and good morning, everyone I'm pleased to be presenting the summary of on the islands Q1, 2023 financial results and discussing our full year guidance.
Starting with a summary of our P&L results for the first quarter.
Total product revenues the quarter over $276 million 48 per cent growth versus Q1 2022.
Previously indicated the increase is primarily related to growth and ctr product revenues driven by the launch of <unk> in the U S and the third quarter of 2022 as well as increased patients on your borrowing Oxley most therapies.
So worth noting that year over year growth and combined product revenues was held back by approximately four percentage points due to impact of changes in foreign exchange rates.
At revenue from collaborations for the first quarter was approximately $36 million, representing a 41% increase compared with Q1 2022, primarily due to an increase in revenue from our collaboration arrangements with regeneron attributed to an increase in reimbursed for activities under our research services arrangement. In addition to an increase in revenue.
Heck ignite associated with license programs within the collaboration.
Royalty revenue during the quarter was $7 million, which was driven by Novartis has sales of <unk>, which launched in the us in the first quarter of 2022.
Gross margin on product sales was 85% in Q1, representing a 2% decrease compared with the first quarter of 2022.
The decrease was primarily driven by increased royalties due to Santa fee on sales of Andrew truck, which was partially offset by lower manufacturing cost ran through in vitro compared with on petrol.
Or non-GAAP R&D expenses increased 35% in the first quarter compared to the same period in 2022, primarily due to increases in head count to support our R&D pipeline development expenses associated with the Apollo B Helios B cardio on cardio too clinical studies and manufacturing related expenses with our pre.
Clinical activities.
Q1, 2022, non-GAAP R&D Opex was disproportionate.
Proportionately lower than all other quarters. During 2022, thus, we expect lower year over year quarterly growth rates for R&D and the remaining quarters of 2023.
Or non-GAAP SG&A expenses increased 17% in the first quarter compared to the same period in 2022, primarily due to increase headcount and other investments supporting our strategic growth, including the global launch of empty.
non-GAAP operating loss for Q1, 2023 was $110 million, representing a $7 million improvement compared with Q1 2022, driven by strong top line growth offset by more moderate growth in operating expenses.
Finally, we ended the quarter with cash cash equivalents and marketable securities of $2.1 billion compared to 2.2 billion at the end of 2022 with the decreased primarily due to our operating loss in the quarter.
Continue to believe our current cash balances sufficient to bridge us to a self sustainable financial profile.
I would like to turn to our full year 2023 financial guidance. We are reiterating the financial guidance. We provided on our year end results call in February starting with that product revenues. We continued to anticipate combined net product revenues for our four commercialized products will be between 1.2 and 128 $5 billion.
Our guidance for net revenue from collaborations in royalties remains a range between 101 hundred $75 million.
And our guidance for combined non-GAAP , R&D and SG&A expenses.
Remains unchanged and has a range between one 575 and $1.65 billion.
I mean downturn from financials and discuss some key goals in upcoming milestones slated for early and mid 2023.
We will of course be executing on global commercialization of our products on <unk> and <unk> give glory and excellent.
From our T. T. R programs, we have a couple of upcoming data presentations.
18 months results from Apollo be will be presented at the Ese heart failure meeting later this month.
And the Helios, a randomized treatment extension results looking at a biannual dose regimen for <unk> will be presented at a SMP also at the end of the bank.
We expect to report topline results from the party of one phase two study <unk> and also intend to complete the enrollment in the cardio to phase two study.
Their partner program severe expects additional results from phase two combination trials of alien HVV O two.
I mean, I will turn it back to Christine coordinator are Q&A session pristine. Thank you John Operator, Bill now open for questions to those Taliban who would like to ask you to limit yourself to one question each and get back in the queue. If you have additional questions.
[noise] Okay. Thank you.
At this time, we will conduct a question and answer session can ask a question you would need to press star one one and your telephone and wait for your needs to be announced to withdraw. Your question. Please press star one line again.
Please stand by while we compile the <unk>.
And our first question comes from reach you <unk> <unk>.
Okay.
Good morning, Guy Thanks for taking the question.
I know I'm, a lonely allowed one so I'm gonna try and stick to it as much as I can the 18 month data.
At work, that's coming up from Apollo B.
Can you talk a little bit more about what will be presented maybe how many patients alright continued follow up 18 months well, we have two secondary and point blank that Kansas City, an additional safety.
Follow up as well thank you.
Yeah.
As a reminder.
Cool Apollo Beeman double blind randomized study 12 <unk>.
And at this point in patients on placebo were given the option to switch to the teacher and for a continuation of Thursday.
These data corroborate really what we saw in the 12 months portion of the study.
And as the notes on the call. We've submitted these days, it's the afternoon will be presenting these data.
Yes in Prague, and May <unk> do you want to add any other comments about the.
The data and.
Engagements with the with.
The agency yeah, absolutely thanks for calling thanks for <unk> for the question.
Yvonne said, we're really excited about these data.
The you asked <unk> about ongoing follow up right. All patients were randomized out the 12 months and then all patients who are offered the opportunity to be an active drug from 12 months and beyond and this is a cut of data out to 18 months.
And we've had very high retention on the study which is important and.
<unk> the profile and I think it's gonna be an opportunity to look at sort of the continued profile of what we've seen on patients on active drug which was we saw evidence of stabilization across key and points, particularly the six minute walk test sort of where it was associated with around the age related decline that theme and that parameter as well as stabilization in.
In the key secondary endpoint of the Kansas City Cardiomyopathy questionnaire.
So that's important as an opportunity to look at the placebo patients as they crossed over to active drug and looking ongoing safety net.
Net net as as auction Yvonne commented rich you were really.
Quite confident and good about the data that we've seen and then it corroborated the profile of <unk> and its potential role in this disease.
As a reminder, we've submitted <unk> safety updates houses routine into submission process.
Thank you next question please.
Thank you.
Alright next question comes.
<unk> <unk> your line is open.
Hi.
Thanks for taking my question.
Maybe just one.
I checked out.
Start.
And ramp I'm just wondering what your.
Data about any kind of market.
Trial.
And whether or not it that is.
You would expect that to be the case going forward as well thanks.
Okay. I think that's one of the guys to you take care of you both hydrazine.
First of all we're incredibly excited the fact that we have been able to build a category add add add essentially you know grow our our business quarter over quarter bite by over 71st said three subsequent quarters of the U S.
Add and what we see in terms of the dynamic with old Petro is a very healthy switch rates, while we're adding that naive patients.
At a very robust matter so what our internal data really suggests is that there is lesser and lesser patients that are stable oil petro as we expect those patients numbers rebated small double digits are single digits overtime.
Okay. Yeah. So we just kind of emphasize how please be out with the launch metrics and <unk> the.
The balance of new patients with lettuce, which isn't really a expansion of the prescribed the price which is very encouraging for continued at.
Growth trajectory.
Check three of our T T R franchise. Thanks.
Thanks, a lot questions <unk>.
Next question please.
Yeah.
[laughter].
Alright next question <unk> <unk> <unk> <unk>.
Yep.
Hi, Thanks, so much for taking my question. This is Sarah on for Alley.
Uhm.
I E. R. C. A program I guess can you talk about some of the timelines there and maybe the prioritization of that versus Alzheimer's and how we should think about the size of the <unk>.
Market opportunity.
Yeah. Thanks for that question I guess that question has been.
Simulated actually by the incredible results that we send them quite remarkable results that we send in a phase.
Phase one interim study and clearly that's the <unk>.
Step in in you know the <unk>.
Bringing on our therapy six the patience with CNS diseases in general liquidity, starting off with early onset Alzheimer's disease, but but this call I think chemistry amyloid angiopathy get another very important opportunity.
Essentially for alien ACP uhm, given the genetics, but could you say a few words about how how we're thinking about the opportunities yeah, absolutely. Thanks Ivan thing Sara look at is has been highlighted by both auction Yvonne.
C. A is it really a devastating disease is the second leading cause of interest ruble haemorrhage only behind hypertension.
Hi, This is the banking on Sir David So we wanted to ask like that the ETS. Please appears likely to have in a decent I T. T. I silence of anti how does that companies since he calls me getting your offerings and eventually I can't take it day, maybe one more time as you mean.